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ABSTRACT
A TG microsatellite in the 30-untranslated region
(UTR) of FGF9 mRNA has previously been shown
to modulate FGF9 expression. In the present study,
we investigate the possible interacting protein that
binds to FGF9 30-UTR UG-repeat and study the
mechanism underlying this protein–RNA interaction.
We first applied RNA pull-down assays and LC-MS
analysis to identify proteins associated with this
repetitive sequence. Among the identified proteins,
FUBP3 specifically bound to the synthetic
(UG)15 oligoribonucleotide as shown by supershift
in RNA-EMSA experiments. The endogenous FGF9
protein was upregulated in response to transient
overexpression and downregulated after
knockdown of FUBP3 in HEK293 cells. As the
relative levels of FGF9 mRNA were similar in these
two conditions, and the depletion of FUBP3 had no
effect on the turn-over rate of FGF9 mRNA, these
data suggested that FUBP3 regulates FGF9 expres-
sion at the post-transcriptional level. Further exam-
ination using ribosome complex pull-down assay
showed overexpression of FUBP3 promotes FGF9
expression. In contrast, polyribosome-associated
FGF9 mRNA decreased significantly in FUBP3-
knockdown HEK293 cells. Finally, reporter assay
suggested a synergistic effect of the (UG)-motif
with FUBP3 to fine-tune the expression of FGF9.
Altogether, results from this study showed the
novel RNA-binding property of FUBP3 and the inter-
action between FUBP3 and FGF9 30-UTR UG-repeat
promoting FGF9 mRNA translation.
INTRODUCTION
Microsatellites (MSs) are simple sequence repetitive motifs
that are ubiquitous and frequently polymorphic in mam-
malian genomes. More than 30000 MSs have been
identiﬁed so far (1) and they comprise  3% of the
human genome (2). Many studies have demonstrated
that MSs in the non-coding region function in gene regu-
lation, presumably by forming speciﬁc DNA structures-
like Z-DNA (3) or H-DNA (4). In addition, tissue- and
cell type-speciﬁc regulation of polymorphic MS motifs on
target gene expression has been reported for human
SNCA (5), TH (6), and HMGA2 (7); this suggests a
common mechanism for this type of regulation.
Furthermore, these ﬁndings indicate that the different
effects might be controlled by the interacting proteins
that are expressed in various cells and tissues and bind
to these regulatory elements (7).
Increasing numbers of MSs have been found in the
UTRs of protein-coding genes and have quantitative
effects on gene expression through post-transcriptional
regulation (8). For example, CA dinucleotide repeats in
the 30-UTR of the mouse CD154 gene regulates CD154
expression by poly(A) tail shortening (9). CA repeats in
the 30-UTR of human Bcl-2 mRNA also contribute to
constitutive mRNA decay (10). Furthermore, a (T)8 MS
motif embedded in the 30-UTR of human CEACAM1
gene forms a hairpin structure and contributes to
mRNA stability (11). Evidence from other species also
showed that RNA-binding proteins regulate mRNA sta-
bility or translation through the binding to 30-UTR UG
repeats. For example, one of the circadian controlled
translational regulators (CCTRs) in green algae,
CHLAMY 1, negatively regulates the activity of
nitrogen metabolism components by binding to UG
repeats residing in the 30-UTR of those genes (12).
Results from these studies revealed that MS repeats par-
ticipate in different mechanisms to regulate gene expres-
sion and the speciﬁcity of the effect depends on the
interacting protein.
Fibroblast growth factor 9 (FGF9) is a member of the
secreted polypeptide family (13) and involved in many im-
portant processes, including developments of lung (14)
and bone (15), and steroidogenesis in postnatal Leydig
cells (16). In addition, Fgf9 knockout mice demonstrate
male-to-female sex reversal, revealing a novel role for Fgf9
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The expression of Fgf9 mRNA is ubiquitous at the early
stage of embryonic development (17), but restricted to a
few organs, including brain, kidney (18) and endometrium
(19). Furthermore, abnormal expressions of FGF9 has
been implicated in pathogenic conditions like glioma
(20), prostate cancer (21), ovarian endometrioid adenocar-
cinoma (22), colorectal carcinoma (23) and endometriosis
(19,24). These studies demonstrated that the expression of
FGF9 must be tightly controlled. Unlike studies have
shown that FGF9 is transcriptionally induced by many
factors like prostaglandin E2 (PGE2) (25) and estrogen
(24), the mechanisms involved in its post-transcriptional
regulation remain largely unknown and are just starting to
be illustrated. A previous study in our laboratory found
that FGF9 has a TG MS in its 30-UTR. The TG MS is
polymorphic in Han Chinese population [i.e. (TG)13–16]
and exhibits function to control FGF9 mRNA stability
(26). Although the study provided the ﬁrst evidence that
the expression of FGF9 can be controlled post-
transcriptionally, the factors involved and the underlying
mechanism of this regulation remain unidentiﬁed and
merit further investigation. Here, we report our ﬁndings
on the identiﬁcation of a putative RNA binding protein,
FUBP3, which interacts with FGF9 30-UTR UG repeats
and positively controls FGF9 expression through
increasing translation of FGF9 mRNA.
MATERIALS AND METHODS
Cell lines and plasmids
Human embryonic kidney 293 cells (HEK293) were rou-
tinely maintained in Eagle’s Minimum Essential Medium
(MEM) supplemented with 10% horse serum and 1mM
sodium pyruvate under 5% CO2 at 37 C. In addition, the
pluripotent human testicular embryonic carcinoma cell
line, NTERA-2c1.D1 (NT2D1), which has the ability to
be differentiated to neuronal cells was also used in this
study. The NT2D1 cells were routinely maintained in
Dulbecco’s Modiﬁed Eagle Medium (DMEM) with
4mM L-glutamine, 4.5 g/l glucose, 1.0mM sodium
pyruvate and 10% heat-inactivated fetal bovine serum
under 5% CO2 at 37 C.
The cloning vectors of pcDNA3.1 myc/His A+
(Invitrogen), pGL3-P (Promega, Madison, WI, USA),
and pRL-TK (Promega) were used in the construction
of various recombinant clones. Full-length CDS of
human FUBP3 (nucleotides 106–1830 of NM_003934)
was ampliﬁed by PCR using primers for FUBP3
(Forward: 50-GTA ATG GCG GAG CTG GTG-30 and
Reverse: 50-GTC CTA CTG CTC CTG GCT GT-30) and
cloned into yT&A vector (Yeastern Biotech, Taipei,
Taiwan). The yT&A-FUBP3 clone was digested with
HindIII and XbaI and subcloned into pcDNA3.1 myc/
His A+ to obtain the pcDNA-FUBP3. Various pGL3-
(TG)n plasmids were constructed by digesting constructs
(26) with AvrII and XbaI enzymes to obtain partial FGF9
30-UTR sequences containing different TG repeats (nu-
cleotides 1605–2161 of NM_002010), and subcloned into
pGL3-promoter. Plasmids for in vitro transcription assays
were constructed by PCR ampliﬁcation of FGF9
(NM_002010, nucleotides 1605–2161) and GAPDH
(NM_002046, nucleotides 628–1079) fragments using
primers for FGF9 (Forward: 50-GCT TGG ATG GGA
ATA TGC TG-30, Reverse: 50-AAA ATG CCT ATC
TGG CCT GT-30) and GAPDH (Forward: 50-ACC
ACA GTC CAT GCC ATC AC-30; Reverse: 50-TCC
ACC ACC CTG TTG CTG TA-30), followed by cloning
into yT&A vector (Yeastern Biotech).
In vitro transcription
To prepare riboprobes for the in vitro binding assay,
FGF9 and GAPDH plasmids were linearized by BamHI
or XbaI restriction enzymes. One microgram of plasmid
DNA was used as template for synthesizing T7-containing
PCR products at their 50- (for sense transcript) or 30- (for
antisense transcript) ends, then transcribed in vitro using
biotin-11-CTP (Roche) as one-tenth of total CTP.
RNA secondary structure prediction
Sequences from FGF9 30-UTR (nucleotides 1465–2077 of
NM_002010) were subjected to secondary structure pre-
diction using the minimum free energy method imple-
mented in the RNAfold web server [http://rna.tbi.univie
.ac.at/cgi-bin/RNAfold.cgi; (27)]. The graphic output was
used for visual comparison at the region of interest.
UV-cross-linking
To conﬁrm that the sequence of FGF9 30-UTR TG
repeats indeed does form RNA–protein complexes,
biotinylated (UG)15 oligoribonucleotide were synthesized
(Integrated DNA Technologies, Inc., Coralville, USA)
and used for further analysis. UV-cross-linking experi-
ments were carried out according to the procedure
described earlier (28). Brieﬂy, the RNA–protein binding
reaction was performed in 10ml containing 1  binding
buffer (10mM HEPES, 3mM MgCl2, 5% glycerol and
1mM DTT), 100mM KCl, 0.5mg/ml yeast tRNA, 20U
RNasin (Promega), 5mg of protein extract, various
amounts of unlabeled RNA probe and 20fmol of
biotinylated (UG)15 probe. After 20-min incubation at
room temperature, 50mg of heparin was added and
irradiated for 30min on ice with a UV-cross-linker
(Stratagene). Samples were separated by 8% SDS–
PAGE under denaturing conditions and blotted to
PVDF membranes using a Mini Trans-Blot cell
(Bio-Rad). RNA–protein complexes were detected with
a LightShift Chemiluminescent EMSA Kit (Thermo sci-
entiﬁc) according to the manufacturer’s recommendations.
RNA-electrophoretic mobility shift assay
RNA-electrophoretic mobility shift assay (RNA-EMSA)
was conducted in 10ml containing 1  EMSA binding
buffer (10mM Tris, 50mM KCl, 1mM DTT), 2.5%
glycerol, 0.05% NP-40, 10U RNasin (Promega),
0.5mg/ml yeast tRNA, 1–2mg of protein extract, unlabeled
probe, 10fmol biotinylated (UG)15 probe and nuclease-
free water. For supershift assay, 1ml of anti-FUBP3
antibody (sc-1110, Santa Cruz) or an equal amount of
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at room temperature for 20min. This was followed by
adding 50mg of heparin into the reaction mix and
incubated for 10min. RNA–protein complexes were
detected and analyzed using the LightShift
Chemiluminescent EMSA Kit (Thermo scientiﬁc) accord-
ing to the suggested protocol.
Identiﬁcation of proteins interacting with FGF9 30-UTR
TG repeats
To identify proteins that speciﬁcally bind to FGF9 30-UTR
UG repeats, biotinylated (UG)15 oligoribonucleotide was
used in pull-down assays. Cytoplasmic extract was
prepared with NE-PER reagents (Thermo Scientiﬁc) in
the presence of 1  complete protease inhibitors cocktail
(Roche) and quantiﬁed by MicroBCA Protein Assay Kit
(Thermo scientiﬁc). Approximately 200fmol of
biotinylated (UG)15 oligoribonucleotides were
immobilized to 1mg of streptavidin-conjugated
Dynabeads (Invitrogen) according to the manufacturer’s
recommendations. Cell lysates containing 100–200mgo f
proteins were incubated with 400mg RNA probe-coated
Dynabeads in a total volume of 500ml. The experiment
was conducted as in the UV-cross-linking assay without
the cross-linking step. The reaction with no biotinylated
oligoribonucleotides was conducted in parallel to serve as
a control. After extensive washing with 1  binding buffer,
the precipitated proteins were separated on 4–12%
NuPAGE in denaturing conditions (Invitrogen) and
visualized by silver staining (29). The differentially
stained bands were excised and submitted for protein iden-
tiﬁcation using the LC/MS/MS service provided by the
Proteomics Research Core at National Cheng Kung
University. The searches for matched peptides were done
by the Mascot algorithm (www.matrixscience.com).
Reverse transcription and conventional RT-PCR
One microgram of total RNA was isolated and reverse
transcribed to cDNA by High-Capacity cDNA Reverse
Transcription Kits (Applied Biosystems). cDNA was
diluted 2- and 5-fold for conventional and quantitative
RT-PCR. Conventional RT-PCR was carried out with
1x PCR buffer, 3.5mM MgCl2, 0.2mM of each dNTP
Mix Solution, 0.2mM of each primer for FGF9
(Forward: 50-GCG AGG GTG CAG TCT TAC TT-30;
Reverse: 50-CAT AGC GGA CTT TGC CAT TT-30)o r
GAPDH (Forward: 50-ACC ACA GTC CAT GCC ATC
AC-30; Reverse: 50-TCC ACC ACC CTG TTG CTG
TA-30.), 0.05U/ml GoTaq (Promega), 2ml diluted cDNA
and water to a ﬁnal volume of 10ml. The PCR program
was 1min at 94 C followed by 25 or 33 cycles of 30 s at
94 C, 30 s at 55 C and 30 s at 72 C. The reaction was
terminated by 72 C for 1min.
RNA Immunoprecipitation
To conﬁrm RNA–protein interactions, cell lysates were
speciﬁcally prepared from 1 to 5 10
6 HEK293 cells and
used in RNA immunoprecipitation (RNA-IP) assays ac-
cording to the procedure described by Tenenbaum et al.
(30). Brieﬂy, 100mlo f 50% protein G-sepharose beads
(GE Healthcare Bio-Sciences) was pre-coated with 4mgo f
normal goat IgG, or goat anti-FUBP3 at 4 C overnight.
The antibody-coated beads were washed ﬁve times with
ice-cold NT2 buffer (50mM Tris pH 7.4, 150mM NaCl,
1mM MgCl2 and 0.05% NP-40) and resuspended in
850ml of NT2 buffer. Two hundred units of RNase
OUT (Invitrogen), 1mM DTT, 20mM EDTA and
100ml of cell lysate were added to the binding reaction.
After brief centrifugation and removal of a 100-ml aliquot
to represent total cellular mRNA, the messenger
ribonucleoprotein (mRNP) was incubated with
antibody-coated beads for 2h at room temperature.
Immunoprecipitated mRNP complexes were washed six
times with ice-cold NT2 buffer and resuspended in
100ml of NT2 buffer containing 0.1% SDS and 30mgo f
proteinase K. The RNA was released by incubation for
30min at 55 C and isolated by RNeasy mini kit
(QIAGEN, Hilden, Germany). Isolated RNA was
further treated with a DNA-free kit (Ambion) to eliminate
any DNA contamination, and reverse transcribed to
cDNA (Applied Biosystems) for further applications.
Analysis of proteins bound to biotinylated RNA
Plasmids used for in vitro transcription were linearized by
BamHI or XbaI restriction enzymes and 1mg of plasmid
DNA was used as template for the synthesis of biotinylated
transcripts in vitro using biotin-11-CTP (Roche) as
one-tenth of total CTP (31). To pull-down proteins that
bind to RNA probes (32), 100mg of cytoplasmic extract
was incubated with 1mg of biotinylated RNA or equimolar
biotinylated (UG)15 oligoribonucleotides for 1h at room
temperature and subjected to western blotting.
Transient overexpression and shRNA knockdown
In FUBP3 overexpression experiments,  2 10
5 HEK293
cells/ml were inoculated in 24- or 96-well culture plates
1day before transfection. This was followed by transfec-
tion of cells with various constructs using FuGENE HD
Transfection Reagent (Roche) according to the manufac-
turer’s instructions. For endogenous FGF9 analysis, cells
grown on 24-well plates were transfected by pcDNA3.1 or
pcDNA-FUBP3 and incubated for another day. For
reporter gene assay, pcDNA3.1 or pcDNA-FUBP3 was
co-transfected in a mass ratio of 1:5 to pGL3-P or
pGL3-(TG)n reporter constructs and assayed after 1day
by Dual-Reporter Assay (Promega) according to the
manufacturer’s recommendations with minor modiﬁca-
tions. Five microliters of cell lysate was mixed with 25ml
of LAR II reagent to measure the activity of ﬁreﬂy
luciferase, followed by administration of 25ml Stop&Glo
reagent to estimate Renilla luciferase activity for normal-
ization. pRL-TK was used as internal control in a mass
ratio of 1:50 to the reporter plasmid. Total proteins and
RNAs were isolated by RIPA lysis buffer (50mM Tris–Cl,
pH 7.5, 1% NP-40, 0.5% sodium deoxycholate, 0.05%
SDS, 1mM EDTA, 150mM NaCl, 1x complete) and an
RNeasy mini kit (QIAGEN).
As for FUBP3 knockdown experiments, pseudotyped
lentiviruses against GFP (TRCN000072194) and FUBP3
(TRCN0000020576) were generated according to the
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(http://rnai.genmed.sinica.edu.tw/). Stable knockdown
pools were obtained by transducing HEK293 cells with
virus suspension (1:10 volume) and selecting in the
presence of 2mg/ml puromycin for 2–3 weeks. To
perform the knockdown experiments, parental HEK293
cells were substituted with stable knockdown HEK293
cells (GFP or FUBP3) and similar procedures were used
when FUBP3 overexpression was applied.
Enzyme-linked immunosorbent assay
One hundred micrograms of cell lysates from
FUBP3-overexpressing or -knockdown HEK293 cells
were used to determine the amount of FGF9 protein
using enzyme-linked immunosorbent assay (ELISA) ac-
cording to manufacturer’s protocol (R&D Systems,
Oxfordshire, UK). Brieﬂy, diluted capture antibody was
added into 96-well plate and incubated at room tempera-
ture overnight. The antibody was removed from each well
by washing the plate with wash buffer. Non-speciﬁc
binding was blocked by adding Reagent Diluent to each
well and incubated at room temperature for 1h. After
washing with wash buffer, cell lysates and standards
were added to each well and incubated by shaking on an
orbital shaker for 2h at room temperature. After washing
the plate, diluted detection antibody was added and
incubated for 2h at room temperature. After incubating
with streptavidin-HRP and substrate solution each for
20min, stop solution was added to terminate the color
reaction. Optical density (OD) was determined by
reading absorbance at 450nm in an enzyme immunoassay
plate reader. The amount of FGF9 protein was calculated




5 stable knockdown HEK293
cells/ml (GFP or FUBP3) were inoculated in 24-well cell
culture plates for 24h, followed by adding 5mg/ml of
actinomycin D to stop the transcription from the FGF9
promoter. Total RNA was isolated at 0, 15, 30, 60 and
120min thereafter. Relative FGF9 level was normalized to
GAPDH at time zero by quantitative RT-PCR.
Ribosome complex pulldown
To investigate translational activity, ribosome complex
pulldown assay was performed according to the procedure
described in Yeh et al. (33). Brieﬂy, cycloheximide (CHX)
was added to HEK293 cells to a ﬁnal concentration of
100mg/ml. Five min later, cells were harvested in
phosphate-buffered saline (PBS) and pelleted and sus-
pended in lysis buffer (10mM HEPES, pH 7.9, 100mM
KCl, 5mM MgCl2, 1% Triton-X 100, 0.5% sodium
deoxycholate, 10U/ml RNaseOUT, 100mg/ml CHX and
1X protease inhibitor cocktail). Cells were kept on ice for
10min, and lysates were centrifuged at 8000rpm for
10min, and the supernatant was saved as cytoplasmic
lysate. About 2mg of ribosomal protein S6 antibody
(Santa Cruz Biotechnology Inc., CA, USA) was added
to 200mg cytoplasmic lysate and incubated at 4 C
overnight. Protein A/G agarose was added to the
mixture to pull down the ribosome complex. The
mRNAs bound with ribosome complex were extracted
with TRI-reagent and analyzed the FGF9 mRNA expres-
sion level by quantitative RT-PCR.
Sucrose gradient centrifugation and polysomal proﬁles
Prior to lysis, cells were pre-treated with CHX (100mg/ml)
for 5min and collected in PBS containing 100mg/ml CHX.
All subsequent steps were performed at 4 C. Cells were
lysed on ice for 10min in a RSB-150 buffer containing
10mM Tris–HCl, pH 7.4, 3mM MgCl2 and 150mM
NaCl, 100mg/ml CHX, 40mg/ml digitonin (Calbiochem,
San Diego, CA, USA), 20U/ml RNasin (Promega) and
a protease inhibitor cocktail (Thermo Scientiﬁc Inc.,
Bremen, Germany). After incubation on ice, cells were
disrupted by passage ﬁve to six times through a 26-gage
needle. The cell lysates were collected by centrifugation in
a microcentrifuge (5424R, Eppendorf AG, Hamburg,
Germany) at 6000 rpm for 2min, and clariﬁed by
further centrifugation at 11000 rpm for 15min. The
samples were loaded on a linear gradient of 15–40%
sucrose and centrifuged at 38000rpm at 4 C for 3h in a
Beckman SW41 rotor. After centrifugation, the polysome
proﬁle was monitored at 254nm using a fractionation
system (ISCO, Lincoln, NE, USA). Sucrose gradients
were split into 11 subfractions each, starting with 1 (top)
to 11 (bottom). Total RNA was isolated using the phenol–
chloroform extraction followed by ethanol precipitation.
The abundance of FGF9 and GAPDH mRNAs of individ-
ual fraction was measured by quantitative RT-PCR. The
translational efﬁciency was calculated in the ratio of
polyribosome-associated FGF9 or GAPDH mRNAs (7–
11 fractions) to total mRNA (all fractions).
Quantitative RT-PCR
Quantitative RT-PCR of FGF9 and GAPDH was per-
formed with TaqMan assays (Applied Biosystems,
Foster City, CA, USA). The levels of FGF9 mRNA ex-
pression in HEK293 cells with and without FUBP3
overexpression were measured (i.e. the 2
 Ct method)
and normalized to the expression level of GAPDH. All
measurements were performed in triplicate and the
experiments were repeated at least twice.
Western blotting analysis, chemicals and antibodies
All chemicals were from Sigma (Sigma-Aldrich Co.,
Steinheim, Germany). The cocktail of complete protease
inhibitor was provided by Roche (Roche Applied Science,
Indianapolis, USA). Cell culture media and supplements
were from Invitrogen (Invitrogen Inc., Carlsbad, CA,
USA). Primary antibodies used were FUBP3 (sc-11103,
Santa Cruz Biotechnology), GAPDH (sc-32233, Santa
Cruz Biotechnology), AUF1 (07-260, Upstate), and goat
normal IgG (sc-2028, Santa Cruz Biotechnology).
HRP-conjugated secondary antibodies were supplied by
Jackson ImmunoResearch Laboratories, Inc.
Protein blots were blocked with 3% non-fat dry milk
(NFDM) in TBS-T buffer at room temperature for 1h.
Primary antibodies were diluted in blocking buffer or
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Solution 1, TOYOBO Co., Ltd., Japan) and incubated
overnight at 4 C. After extensive washing with TBS-T,
blots were incubated with HRP-conjugated secondary
antibodies in blocking buffer or CanGetSignal Solution
2 (TOYOBO) and detected using chemiluminescent sub-
strate (Millipore, Immobilon) for X-ray ﬁlm exposure.
Statistical analysis
All experimental data were analyzed using GraphPad
Prism 3.0 (GraphPad Software, Inc., San Diego, CA,
USA; www.graphpad.com) and presented as mean±
SEM. Results were further analyzed using t-test or
one-way ANOVA, and post-test was processed using
Newman–Kuels post test. The signiﬁcance level for all
statistical tests was 0.05.
RESULTS
Prediction of FGF9 30-UTR RNA structures
Previously we found the TG MS in FGF9 30-UTR had
four polymorphic alleles [c.*275TG(13_16)] in Han
Chinese population and different lengths of the TG
repeat affected luciferase gene expression (26). To investi-
gate whether any sequence motifs are embedded in the TG
repeats of FGF9 30-UTR, the 613nt downstream from the
coding region of human FGF9 (Figure 1A) were submitted
for secondary structure prediction by RNAfold (27). The
30-UTR sequence of human FGF9 is highly structured as
indicated by the presence of many stems and loops
(Figure 1B). Interestingly, different repeat numbers in
the UG MS inﬂuence the local folding of RNA, and the
varied structures contain different numbers of stem–loops
with different minimal free energy (MFE) (Figure 1C).
Among these, (UG)13 and (UG)14 are similar in their
structures and folding MFE. Likewise, (UG)15 and
(UG)16 are similar in their structures and folding MFE.
We therefore hypothesized that the predicted secondary
structures of human FGF9 30-UTR sequences, especially
around the UG-repeat region can be recognized by speciﬁc
RNA-binding proteins and the interaction between FGF9
RNA and protein may affect the FGF9 expression.
Speciﬁc proteins bind to (UG)15 oligoribonucleotide
To determine whether speciﬁc proteins bind to (UG)n
repeat motifs to form RNA–protein complexes, synthetic
(UG)15 oligoribonucleotide, the dominant allele of the UG
MSs in human FGF9 30-UTR (26), was incubated with
cytoplasmic or nuclear extracts prepared from HEK293
and NT2D1 cells. Two major protein groups ranging
from 55 to 70kDa and  130kDa were detected by
UV-cross-linking assays (Figure 2A). The speciﬁcity of
the interaction between UG repeats and protein extracts
was conﬁrmed by competition assays showing that the
binding afﬁnity of these proteins was reduced with
increased doses of unlabeled probes. Moreover, the
RNA–protein interaction was stronger in nuclear than
cytoplasmic extract. Similar results were obtained using
the RNA-EMSA approach. At least six RNA–protein
complexes (C1–C6) were formed in both cytoplasmic
and nuclear extracts (Figure 2B). Together, these data
showed that the structural motif of the (UG)15 MS at-
tracted many proteins to form RNA–protein complexes.
To identify the speciﬁc (UG)n–binding proteins,
biotin-labeled (UG)15 oligoribonucleotide was used as a
bait to pull down interacting proteins from HEK293
cells. Compared with the control, silver stain revealed
several differentially pulled-down proteins (Figure 2C).
Following LC–MS–MS analysis, many proteins were
identiﬁed as potential (UG)15-binding proteins
(Figure 2C and Table 1). The identiﬁed proteins, their
identiﬁcation scores, and sequence coverage are provided
in Table 1. Among these, the molecular weights of far
upstream element (FUSE) binding protein 3 (FUBP3),
Ras-GTPase-activating protein SH3-domain-binding
protein (G3BP1), non-POU domain containing
octamer-binding (NONO), vimentin (VIM), and DNA
polymerase delta interacting protein 3 (POLDIP3)
isoform 1, ranged between 55 and 70kDa and represented
the most promising candidates for further investigation.
FUBP3 binds to FGF9 30 (UG)15
We carried out RNA-EMSA with speciﬁc antibodies to
conﬁrm the binding of identiﬁed proteins to (UG)15
sequence. The presence of many RNA–protein complexes
in protein extracts incubated with (UG)15 oligoribo-
nucleotide only was in agreement with the results shown
in Figure 2B (Figure 3A). Among four proteins examined,
a distinct complex formed by the (UG)15 probe interacted
with anti-FUBP3 antibody in HEK293 cells (Figure 3A,
lane 3 in left panel). Furthermore, a weak but detectable
supershift was also observed with anti-FUBP3 antibody in
the NT2D1 cells (Figure 3A, lane 2 in right panel), but not
with mouse IgG (Lanes 1 and 3 in the right panel);
complete disappearance of the C3 band was accompanied
by a band shift (Figure 3A). It is of note that the inter-
action between FUBP3 and the (UG)15 probe was speciﬁc
to the cytoplasmic fraction (Lanes 1–6 and 1–2 in left and
right panel, respectively) but not the nuclear fraction
(Lanes 7–12 and 3–4 in left and right panel, respectively).
To conﬁrm FUBP3 binding to the (UG)15 of FGF9
mRNA, we ﬁrst applied the original membrane used in
UV-cross-linking experiment for western blot analysis.
Using FUBP3-speciﬁc antibody, our data showed a
signal locates on the top of 55–70kDa cluster that indi-
cates FUBP3 (Supplementary Figure S1). Further,
biotin-labeled (UG)15 oligoribonucleotide or in vitro
transcribed FGF9 30-UTR RNA were used to pull down
interacting proteins from HEK293 cytoplasmic extract,
while in vitro-transcribed GAPDH was used as negative
control. It was clearly demonstrated that both
biotin-labeled (UG)15 and FGF9 30-UTR RNA, but not
GAPDH, interacted with FUBP3 protein (Figure 3B, top
panel). In addition, AU-rich element (ARE) binding
factor 1 (AUF1), that is known to control FGF9 gene ex-
pression by interacting with the FGF9 30-UTR ARE (34),
was present in the protein pools pulled down by FGF9 30-
UTR RNA but not (UG)15 oligoribonucleotide
(Figure 3B, bottom panel), thus suggesting that the
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speciﬁc. We then investigated the ability of FUBP3 to
bind to the FGF9 (UG)15 in vivo. HEK293 cell lysates
were immunoprecipitated with anti-FUBP3 antibody
and the presence of endogenous FGF9 mRNA in the
immunoprecipitates was determined by quantitative
RT-PCR. A distinct PCR product was detected in the
immunoprecipitates for FGF9, but not for GAPDH, and
a 4.25-fold enrichment of FGF9 level in the immunopre-
cipitates for FUBP3 relative to those for IgG was obtained
(Figure 3C). Collectively, these data demonstrated that
FUBP3 speciﬁcally binds to FGF9 30-UTR (UG)15 and
the interaction may participate in the regulation of
FGF9 gene expression.
FUBP3 positively regulates FGF9 expression through an
increase in translational efﬁciency
To address how FUBP3 interacts with FGF9 30-UTR
(UG)15 and participates in the regulation of FGF9 gene
expression, we ﬁrst determined the level of endogenous
FGF9 in response to alteration of the cellular level of
FUBP3 in HEK293 cells. Either full-length FUBP3
cDNA or FUBP3-speciﬁc shRNA constructs were trans-
fected into HEK293 cells. The overexpression or
knockdown of FUBP3 expression was conﬁrmed by
western blot using anti-FUBP3 antibodies (Figure 4A,
top panel) and the levels of FGF9 mRNA and protein
were measured. While the levels of FGF9 mRNA were
similar in response to FUBP3 overexpression (1.16±
0.01) and knockdown (1.19±0.04) (Figure 4A, middle
panel), FGF9 protein increased to 1.12-fold (P=0.056)
under FUBP3 overexpressing condition and signiﬁcantly
declined to 0.81-fold (P<0.01) in FUBP3-knockdown
cells (Figure 4A, bottom panel). These data showed that
the FUBP3 had no effect on FGF9 transcription and sug-
gested that FUBP3 regulates FGF9 expression at the
post-transcriptional level by stabilizing mRNA or
increasing translational efﬁciency.
To deﬁne the physiological signiﬁcance of the inter-
action between FUBP3 and UG repeats in the regulation
of FGF9 expression, we determined the decay of FGF9
mRNA either with or without FUBP3 using a cell-based
Figure 1. FGF9 30-UTR RNA structure prediction. (A) Sequence analysis of human FGF9 30-UTR. The sequence corresponding to the 30-end of the
gene is depicted. The TGA nucleotide sequence marked in bold type corresponds to the translation stop codon. The (GA) and (TG) MS motifs are
marked in bold and underlines, and the AU-rich element (ARE) sequence and poly-A signals are marked with double underlines. (B) Representative
RNA structure of full-length FGF9 30-UTR sequence (NM_002010; 613nt). (C) Enlargement of boxed area in B. Curved lines mark the locations of
indicated UG repeats. MFE of predicted structure under each indicated UG repeat in units of kcal/mol.
Nucleic Acids Research,2011, Vol.39, No. 9 3587Figure 2. Riboprotein complex formation by UG repeats of FGF9 30-UTR. (A) UV-cross-linking was conducted using biotinylated (UG)15 oligoribo-
nucleotide and protein extracts (cytoplasmic extract, CE; nuclear extract, NE) prepared from HEK293 (left) and NT2D1 (right) cells. Excess molar
ratio of unlabeled cold probe was added as indicated in the competition assay. (B) The same labeled probe, cold probe and protein extracts as in (A),
were used in RNA-EMSA and showed similar results in HEK293 (left) and NT2D1 (right) cells. C1–C6: complexes 1–6. (C) (UG)15 binding proteins
identiﬁed by LC–MS. Proteins pulled down in the absence (left lane) or the presence of riboprobe (UG)15 (right lane) were assayed by silver stain.
Differentially expressed bands (marked by 1–8) were excised for protein identiﬁcation by LC–MS.
Table 1. Proteins identiﬁed by LC/MS/MS
No.
a Gene name (gene symbol) Matched Gene ID Mass (kDa) Score Coverage (%)
1 Splicing factor proline/glutamine-rich (polypyrimidine tract
binding protein associated), isoform CRA_a (SFPQ)
gi|119627826 105 506 22
2 FUSE binding protein 3(FUBP3) gi|100816392 67 123 17
3 Ras-GTPase-activating protein SH3-domain-binding protein
(G3BP1)
gi|5031703 65 180 22
4 Non-POU domain containing, octamer-binding (NONO) gi|34932414 62 633 20
5 Vimentin (VIM) gi|340219 58 108 28
6 DNA polymerase delta interacting protein 3 isoform
1(POLDIP3)
gi|29837655 56 234 24
7 TAR DNA binding protein (TARDBP) gi|6678271 47 235 16
8 Cleavage and polyadenylation speciﬁc factor 5 (NUDT21) gi|5901926 30 126 14
aNo: number. The number follows the order indicated in Figure 2C.
3588 Nucleic Acids Research, 2011,Vol.39, No. 9decay system. FUBP3-speciﬁc shRNA was transfected
into HEK293 cells to knockdown the FUBP3 expression
and the effect on mRNA stability in cells with and without
FUBP3 knockdown were measured and compared. After
0, 15, 30, 60 and 120min after adding actinomycin D (Act
D), RNA was extracted and the relative amounts of FGF9
to GAPDH mRNA at different time points were measured
using quantitative RT-PCR. The two regression lines
almost overlapped and the estimated half-life (t1/2) for
cells transfected and untransfected with FUBP3 shRNA
were the same (P=0.58; Figure 4B). As the stability of
FGF9 mRNA did not change upon FUBP3 depletion,
these results ruled out the possibility that FUBP3 regu-
lates FGF9 expression through mRNA stabilization and
suggested that FUBP3 contributes to FGF9 expression
through an increase in translational efﬁciency.
To test whether FUBP3 translationally controls
endogenous FGF9 protein expression, we ﬁrst performed
ribosome complex pulldown assay (33) under the
condition of overexpressing FUBP3. RNA was isolated
from the immunoprecipated pellet as well as the initial
lysate, and ampliﬁed using quantitative RT-PCR. We
found that overexpression of FUBP3 protein increased
the ribosome-bound FGF9 mRNA by  1.7-fold
(P=0.001; Figure 4C, left) while there was no difference
of FGF9 mRNA level in the initial lysates (Figure 4C,
right). Next, we conducted sucrose gradient analysis of
ribosome-bounded FGF9 mRNA to examine the FGF9
translational efﬁciency in FUBP3-knockdown HEK293
cells. The polysome proﬁling revealed that translational
efﬁciency of FGF9 mRNA drops 13% (P<0.002; Figure
4D, right) while there is no change in the translational
efﬁciency of GAPDH gene (Figure 4D, left). Taken
together, these results support our hypothesis that
FUBP3 positively regulates the FGF9 protein expression
by promoting translational activity.
Synergistic effect of FUBP3 with FGF9 (UG)n repeats
Four alleles with different length of TG repeats in FGF9
30-UTR were found in Han Chinese (26). To determine
whether various numbers of UG repeats inﬂuence the
interaction with FUBP3 and thus have different effects,
Figure 3. Identiﬁcation of FUBP3 as UG-repeat binding protein. (A) The RNA–protein complex was detected using speciﬁc antibodies as indicated
in RNA-EMSA in the protein extracts from NT2D1 (left) and HEK293 (right) cells. CE, cytoplasmic extract; NE, nuclear extract. IgG was used as a
control. (B) Pull-down assays were performed using biotinylated (UG)15 riboprobe and in vitro-transcribed FGF9 30-UTR containing (UG)15 repeats
in the cytoplasmic extract from HEK293 cells. Speciﬁc antibodies to FUBP3, GAPDH and AUF1 were used to detect the pulled-down proteins. H2O
and in vitro-transcribed GAPDH probe were used as negative controls for pull-down assays. (C) Immunoprecipitated RNA–protein complexes using
anti-FUBP3 antibody showed the presence of endogenous FGF9, but not GAPDH mRNA in HEK293 cells (lane 2). Goat normal IgG was used as a
control for the immunoprecipitation reaction. The enrichment of FGF9 mRNA precipitated by anti-FUBP3 antibody is shown relative to goat
normal IgG. Data were normalized to GAPDH.
Nucleic Acids Research,2011, Vol.39, No. 9 3589we used constructs containing different numbers of TG
repeats (Figure 5A) in reporter gene assays under
FUBP3 overexpression or knockdown in HEK293 cells.
Overexpression of FUBP3 signiﬁcantly promoted reporter
gene activity (Figure 5B). In addition, reporter constructs
containing (TG)13 (P<0.01) and (TG)14 (P<0.01) repeats
had a more prominent effect than that containing (TG)16
repeats in responding to FUBP3 overexpression. On the
other hand, the structural effect of (TG) repeat in FUBP3
knockdown cells was not statistically distinguishable
(Figure 5C). These data mirror the results presented in
the structure prediction (Figure 1B) and suggest that the
number of TG repeats in FGF9 30-UTR and levels of
FUBP3 protein collaboratively ﬁne tune the expression
of FGF9.
DISCUSSION
In the present study, we found that FUBP3 is able to
interact with FGF9 30-UTR (UG) repeats to control
FGF9 expression in both HEK293 and NT2D1 cells.
Furthermore, FUBP3 overexpression or knockdown
resulted in an increased or reduced FGF9 expression.
Figure 4. FUBP3 increased the expression of endogenous FGF9 and reporter proteins containing FGF9 30-UTR. (A) Representative western blots
and RT-PCR results from transient FUBP3 overexpression and shRNA knockdown. Endogenous FUBP3 (ﬁlled triangle) and overexpressed FUBP3
(open triangle) were shown in the top panel. Relative mRNA level (RT-PCR; middle panel) and protein amount (ELISA; bottom panel) were shown
under each treatments. (B) RNA stability assay showed that knockdown of FUBP3 had no effect on FGF9 turn-over rate. (C) FUBP3 overexpression
promotes FGF9 protein synthesis in HEK293 cells. The ribosome complexes were pulled down by 40S ribosomal protein S6 antibody from HEK293
cells overexpressing recombinant FUBP3. The mRNAs bound with ribosome complexes were extracted and analyzed by quantitative RT-PCR. FGF9
mRNA expression level was detected and normalized with the mRNA expression level of GAPDH. The total RNA was also extracted from HEK293
cell with or without FUBP3-overexpression (Right), and the FGF9 mRNA level was detected as an experimental comparison to the results showed in
(Left). (D) Relative translational efﬁciency representation of FGF9 and GAPDH in the polysomal fractions. Ribosome-associated transcripts were
measured using quantitative RT-PCR and translational efﬁciency of FGF9 and GAPDH under FUBP3-knockdown were normalized with the
translational efﬁciency in GFP-knockdown cells. **P<0.01; ***P<0.001.
3590 Nucleic Acids Research, 2011,Vol.39, No. 9We also demonstrated, while depletion of FUBP3 had no
effect on FGF9 mRNA stability, the altered FGF9 protein
expressions under FUBP3 overexpression and knockdown
are in association with concordant changes of
ribosome-bound FGF9 mRNAs. These results show that
FUBP3 regulates FGF9 expression through a mechanism
involved in translational efﬁciency.
FGF9 is a potent mitogen, angiogenic, osteogenic and
morphogenic factor besides its role in lung (review see (35)
and gonad developments [review see (36)]. Aberrant ex-
pression of FGF9 usually results in dramatic effects in
physiological and pathological processes. Thus, FGF9 ex-
pression needs to be tightly controlled to properly regulate
various physiological processes. In this study, we found
that knockdown of FUBP3 reduced FGF9 protein by
20%, a change that is not enormously huge but should
be biologically relevant. It is quite common under physio-
logical conditions that small ﬂuctuation of ligands (such as
neurotransmitters or ions) usually leads to a series of chain
reaction that ultimately results in huge physiological
response. Behr et al. (37) demonstrated in a mouse
model that only 50% decrease in fgf9 (i.e. fgf9
+/ )
severely impair bone repair and vessel formation.
Considering that FGF9 modulates various signaling
pathways including VEGF (38) and sonic hedgehog (39),
and the knockdown is not 100% efﬁcient in the current
study, the actual magnitude of FUBP3-regulated FGF9
protein expression might be greater and effect of FGF9
will be augmented in vivo.
Human FUBP3 belongs to a regulatory gene family
consisting of three members, FUBP1, KH-type splicing
regulatory protein (KHSRP, also known as FUBP2),
and FUBP3 (40). Although the three members share
highly conserved sequence and structure (40), their func-
tions are quite diverse. FUBP1 is a single-strand DNA-
binding protein which activates c-myc proto-oncogene ex-
pression by binding to the non-coding strand cis FUSE,
encompassing positions  1554 to  1526 of c-myc (41).
KHSRP interacts with ARE-containing mRNAs and is
a key mediator of mRNA decay (42). Independent of
the role in RNA degradation, KHSRP also regulates the
maturation of a subset of miRNAs (43). Although FUBP3
is the strongest activator among this family (44), it has no
effect on the transcription of FGF9 as shown in this study
and a survey of genes regulated by siFBPs (44). Our data
indicated that FUBP3 executed its effect at the
post-transcriptional rather than at the pre-transcriptional
level. Unlike the other two members, there was no
Figure 5. Synergistic effect of FUBP3 with FGF9 (UG)n repeats. (A) Schematic diagram of reporter constructs containing partial FGF9 30-UTR with
various TG repeats. Reporter activities of various constructs from HEK293 cells overexpressing (B) or knockdown (C) FUBP3. All values were
normalized to Renilla luciferase activity produced from a cotransfected control plasmid. Error bars represent standard deviations from three inde-
pendent transfections. Statistical analyses were conducted by one-way ANOVA. *P<0.05; **P<0.01.
Nucleic Acids Research,2011, Vol.39, No. 9 3591evidence indicating an association of FUBP3 with
RNA (42,45,46). The subcellular localization of FUBP3
in both cytoplasm and nucleus also distinguished it from
the other two, that were restricted to the nucleus (44),
implying its distinct role in gene regulation. However,
we here report the ﬁrst evidence that FUBP3 binds to
FGF9 mRNA and the speciﬁc protein–RNA interaction
translationally controls FGF9 gene expression.
Earlier, we provided evidence that the TG repeat
located on the FGF9 30-UTR is a functional element that
controls FGF9 mRNA stability and regulates FGF9
expression (26). It is worth noting that the factor we
identiﬁed in this study, FUBP3, has no destabilizing
effect on FGF9 mRNA. Instead, it positively regulates
FGF9 expression through a mechanism related to trans-
lational efﬁciency. Thus though FUBP3 binds to FGF9
UG repeats and contributes to the regulation of FGF9
expression, it is not the factor we originally found in
our earlier study. Indeed, data from RNA-EMSA
demonstrated that at least six proteins can form complexes
with (UG)15 riboprobe in the cytoplasmic fraction, while
ﬁve protein–RNA complexes were found in the nuclear
fraction. These studies demonstrated that other factors
are involved in the regulation of FGF9 mRNA stability.
Nevertheless, the FUBP3-(UG)15 complex only exists in
the cytoplasmic fraction (i.e. C3 complex), suggesting the
effect of FUBP3 is involved in the later process of gene
expression where the interaction mainly occurs in the cyto-
plasmic compartment.
Recent studies demonstrated that mRNAs that encode
proteins with similar functions are coordinately regulated
by the same RBP to form a post-transcriptional network
called an RNA regulon (47). On the other hand, many
RBPs may coordinately bind to the same transcript to
regulate gene expression. Beside the TG repeats, we also
found a functional AU-rich element (ARE) in the 30-UTR
of the FGF9 gene. The interaction between FGF9 ARE
and AU-rich element binding protein 1 (AUF1) contrib-
utes to the destabilization of FGF9 mRNA and leads to a
reduction of FGF9 expression (34). Together with the
ﬁndings from this study, these results demonstrated the
presence of two cis-elements that communicate with dif-
ferent cellular factors and trigger different mechanisms to
regulate FGF9 expression post-transcriptionally.
Our team has been engaging to study the function and
regulation of FGF9 for a long time. We are the ﬁrst group
to report FGF9 function is involved in steroidogenesis
(16), and associated with human male-to-female sex
reversal (26) and endometriosis (19). In addition, we
identiﬁed PGE2 promotes FGF9 mRNA expression (25)
and AUF1 downregulate FGF9 mRNA stability (34).
These studies make us believed the expression of FGF9
is under many layers of controls to keep the FGF9 homeo-
stasis in a cell. Our goal is to establish the regulatory
network of FGF9 expression and illustrate the conse-
quence of deregulated FGF9 expression. The current
study demonstrates that translational regulation is
another level that cells will use to regulate FGF9 protein
production, an important step in the central dogma
control of gene expression. Furthermore, results from
this study strongly support the existence of a complex
regulatory network of FGF9 gene expression to
ﬁne-tune FGF9 homeostasis. Finally, our study reports
the novel RNA-binding property of FUBP3 and its role
in regulation of translational efﬁciency. Thus it raises the
possibility that some diseases induced by FGF9
over-expression might be a consequence of FUBP3
dysregulation. Further studies are necessary to elucidate
this proposed possibility.
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